GE Healthcare Announces Phase-I Results For Macrocyclic Manganese-Based MRI Agent

GE Healthcare Announces Phase-I Results For Macrocyclic Manganese-Based MRI Agent. The clinical trial program demonstrates GE HealthCare’s commitment to innovation in contrast media and to building a portfolio of MRI imaging agents to address radiologists’ needs for their patients.

GE HealthCare (Nasdaq: GEHC) has recently announced the completion of its Phase I clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. According to Industry sources, the outcome, which will be utilized to aid ongoing clinical development, concluded that in a first-in-human study, this manganese-based contrast agent was well tolerated […]